Allergy

A study links caregiver beliefs, mental health challenges, multiple allergens, and prior anaphylaxis to worse food allergy–related quality of life in pediatric patients.

Q4 2025 brought key FDA approvals and phase 3 advances in HAE, peanut allergy, multi-allergen immunotherapy, and allergic fungal rhinosinusitis.

December highlights: FDA approval of berotralstat for pediatric HAE, phase 3 RAPIDe-3 results, and allergy field spotlights in our This Year in Medicine series.

Nurse practitioners play a key role in allergy and asthma care using specific IgE blood testing to identify triggers, improve outcomes, and ease shortages.

Significant advancements in allergy treatments emerge in 2025, including 4 FDA approved treatments for hereditary angioedema.

Innovative therapies and devices are transforming food allergy management, enhancing safety and quality of life for patients and families.

Study finds comparable IgE reductions with heated milk and conventional desensitization, but heated milk linked to higher anaphylaxis risk in children with cow’s milk allergy.

DBV Technologies announced that the phase 3 VITESSE trial on VIASKIN® Peanut patch for peanut-allergic children met its primary endpoint.

Stay updated with the latest healthcare breakthroughs, including several new FDA approvals, in this week's essential news roundup.

Berotralstat (ORLADEYO) oral pellets become the first FDA-approved therapy specifically designed to prevent HAE attacks in children aged 2 – 11 years.

A review in Wichita, Kansas, shows asthma-related emergency visits spike during storms, underscoring the importance of weather-based asthma action plans for at-risk patients.

Study shows house dust mite SLIT therapy is safe in children with allergic asthma, though COVID-19–related drops in exacerbations impacted the primary endpoint.

This HCPLive Five features advancements in asthma, immunology, and allergy that were presented at the ACAAI 2025 meeting in Orlando.

Oral bradykinin B2 receptor antagonist resolved HAE attacks in under 90 minutes, with most patients needing only a single dose and no rescue medication.

A survey found many obstetric physicians rarely refer pregnant patients for allergy or immunology care, citing knowledge gaps and long wait times.

Recent advancements in HAE treatments offer hope, but experts stress the need for more pediatric options and diverse therapies.

This month in review spotlights 5 top allergy headlines published in November, including late-breaking data at ACAAI 2025.

A quick guide for clinicians on epinephrine dosing, optimal observation periods, and the role of tryptase and other labs in anaphylaxis care.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new Crohn's disease guidelines, in this week's essential news roundup.

New findings reveal the Viaskin Peanut Patch effectively builds peanut tolerance in over 70% of toddlers, offering hope for allergy management.

Study finds eczema onset at 4–6 months, greater severity, and longer duration linked to lower odds of outgrowing food allergies in children.

At ACAAI 2025, Manning highlighted sustained attack reduction and strong patient preference for donidalorsen across long-term and switch data.

A study presented at ACAAI 2025 reveals HAE attacks may start in toddlers, highlighting significant daily burdens and the importance of timely diagnosis and treatment.

At ACAAI 2025, Trubiano discusses repurposed immunomodulators, T-cell–targeted approaches, and genetic screening for delayed hypersensitivity management.

Children with HAE often face delayed or inconsistent emergency care, with clinicians citing limited condition-specific knowledge as a key contributor.